ENTITY
BeiGene

BeiGene (BGNE US)

140
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
29 Jan 2019 17:27

CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates

CStone Pharma (CSTONE HK) is a biopharmaceutical company which is developing a pipeline of 14 drug candidates of which 9 are in clinical...

Logo
669 Views
Share
15 Jan 2019 09:06

Last Week in GER IPO Research: Leong Hup, China Tobacco, Futu and Weimob

We slide into 2019 with GER's recap of our latest IPO research. This week, we talk chicken as Arun initiates on the IPO Malaysian poultry producer...

Logo
630 Views
Share
bearishTencent Music
17 Dec 2018 09:01

Last Week’s GER IPO Research: Tencent Music, IPO Trading Strategy Deep Dive, WuXi, Junshi & Xinyi

Another busy week for IPO research from the GER team. This week, we recap the Tencent Music Entertainment (TME US) IPO which we noted is more...

Logo
439 Views
Share
11 Dec 2018 09:33

Junshi Bioscience (君实医药) IPO: Rich Valuation, but Catalyst Ahead

Shanghai Junshi Biosciences, a China-based biotechnology company listed on the NEEQ market (ticker 833330.NEEQ) with a market capitalization of USD...

Logo
829 Views
Share
10 Dec 2018 20:12

Junshi Biosciences IPO Valuation: Sensibly Priced with Upside at the Low-End

Shanghai Junshi Bioscience Co. Ltd. (1387344D CH) launched its Hong Kong IPO today. The mid-point of Junshi's IPO price range of HK$19.38-20.38 per...

Logo
516 Views
Share
x